Synchron Secures $200 Million to Advance Stentrode Platform
US-based company Synchron has raised $200 million in a Series D funding round to support the global commercial rollout of its Stentrode brain-computer interface (BCI) and to accelerate development of next-generation neural interfaces.
Investment and Key Backers
The funding round was led by Double Point Ventures with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New investors joining this round include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Strategic Goals of the Funding
Synchron plans to use the latest investment to speed up clinical trials and expand its team across various scientific and engineering disciplines. The company’s goal is to make brain-computer interfaces more accessible and integrated into daily healthcare applications.
CEO’s Statement
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
— Tom Oxley, Founder and CEO of Synchron
Author’s Summary
Synchron’s $200M Series D funding marks a pivotal step toward bringing non-surgical brain-computer interfaces into mainstream medical use, signaling rapid progress in BCI innovation.